Researchers have identified eight distinct genetic "footprints" that are present in approximately 85% of prostate tumors, a discovery that could significantly improve the early detection and personalized treatment of the disease. The findings, published in the journal Nature by the Pan Prostate Cancer Group (PPCG), offer new insights into the biological mechanisms driving prostate cancer, potentially helping to distinguish between aggressive and slow-growing forms.
Four of the identified genetic patterns were specifically linked to cancers that had a higher likelihood of spreading beyond the prostate. This distinction is crucial, as many prostate cancers are diagnosed too late for effective treatment. The study examined tumor samples from 959 men, revealing that prostate cancer is not a singular disease but comprises various forms with different biological behaviors.
"For many years we’ve known that prostate cancer is not a single disease," said Ros Eeles, professor of oncogenetics at The Institute of Cancer Research, London, and co-founder of the PPCG. "Two men may receive the same diagnosis but have cancers that develop and behave very differently, and we have not fully understood the biology behind those differences. Some of these findings are helping us understand aggressive disease, while others are revealing entirely new avenues for research. Our long-term goal is to help ensure that patients receive the right treatment at the right time, based on the biology of their individual cancer rather than a one-size-fits-all approach."
The research also uncovered genetic footprints associated with age and ancestry, noting patterns more common in Black men. Prostate cancer is the most common cancer among men in Britain, with an estimated 63,000 cases and 12,000 deaths annually. Black men have a one in four lifetime risk, double that of the general population, and men with a family history of the disease face a similar elevated risk.
Lead author Professor Joachim Weischenfeldt from the University of Copenhagen highlighted the clinical significance of these genetic markers. "It is remarkable how much clinical significance these genetic fingerprints appear to have," he stated. "They can help distinguish between patients who are developing life-threatening cancer and those who are not." While further clinical studies are required before widespread patient application, these findings represent a significant step toward understanding the biology of aggressive prostate cancer and developing tailored treatments.
Prostate cancer charities have welcomed the findings. Hayley Luxton from Prostate Cancer UK, a co-funder of the study, commented, "At the moment, it’s not obvious which prostate cancers are more likely to spread outside the prostate, which makes it harder for men to receive the best treatment for their individual cancer. These findings from the Pan Prostate Cancer Group are hugely exciting and could lead to men getting the personalised treatment they need for their prostate cancer."